Latest Distribution Channels News

Atomo Diagnostics capitalises on Lumos Diagnostics’ FebriDx FDA CLIA waiver with over $2 million in new sales orders and a $3 million capital raise, expanding its global footprint and product pipeline.

Biome Australia’s Activated Probiotics brand surpasses one million boxes sold in Australia, approaches top pharmacy ranking, and launches nationally in Canada, setting the stage for FY26 profitability.

First Graphene has secured advanced graphene coatings technology through the AU$250,000 acquisition of Ionic Industries and Imagine Intelligent Materials, gaining immediate entry into lucrative geotextile and environmental infrastructure sectors.

Butn Limited has signed a memorandum of understanding with a major global bank to launch buyer-led supply chain finance programs in Australia, leveraging Butn’s proprietary platform and the bank’s funding capacity.

Biome Australia has taken a significant step in its innovation journey by filing a patent for its next generation probiotic strain BMB18, with a clinical trial set to begin in Q4 FY26 in partnership with La Trobe University.

Sarytogan Graphite Limited has upgraded its Central Graphite Zone resource, marking a key milestone with Measured classification and progressing its Definitive Feasibility Study. Meanwhile, copper exploration reveals promising anomalies, backed by fresh capital injections.

N1 Holdings delivered record settlement volumes and a 127% surge in quarterly cash receipts despite challenging market conditions, driven by disciplined funding and operational efficiency.

Treasury Wine Estates is reshaping its global operations into four regional divisions to sharpen market execution and efficiency. The company reports improved third-quarter sales in China and the US, bolstered by luxury brand Penfolds, while securing $300 million in new debt to strengthen liquidity beyond $1 billion by fiscal 2026 end.

MA Financial Group reported a 44% year-on-year jump in assets under management to $14.8 billion in 1Q26, underpinned by strong lending growth and transactional activity despite asset sales and market volatility.

Butn Limited surged to record monthly originations and revenue in March 2026, while cutting costs and completing a share buy-back, underscoring its drive to scale embedded SME funding solutions.

Xenitra Limited’s Q3 sales soared to $8.3 million, a 300% jump over Q2, driven by its Nutritionals division and a strategic $30 million partnership with Rockcheck Group for Danone products. The company also launched new OTC medicines and blockchain tokenised sales channels poised to fuel future growth.

Xenitra Limited has acquired Hong Kong Fukang Trading Co., including key pharmaceutical licenses and ecommerce assets, to fully operationalise its OTC medicine business in Hong Kong and China.